Showing 26–50 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Harris RC, Quaife M, Weerasuriya C, Gomez GB, Sumner T, et al.
…r-olds. Vaccine trials should include adolescents to ensure vaccines can be delivered to this efficient-to-target population.
Asante KP, Mathanga DP, Milligan P, Akech S, Oduro A, et al.
Background The RTS,S/AS01 E malaria vaccine (RTS,S) was introduced by national immunisation programmes in Ghana, Kenya, and Malawi in 2019 in large-scale pilot schemes. We aimed to address questions about feasibility and impact, and to assess safety signals that had been observed…
Kurtz SL, Mittereder LR, Lehman CC, Khan H, Gould VA, et al.
Tuberculosis is still the leading cause of death globally from any infectious disease, despite the widespread use of the live attenuated vaccine Bacille Calmette Guerin (BCG). While BCG has some efficacy against disseminated TB disease in children, protection wanes into adulthood…
Roordink D, Williams A, Fritzell B, Laddy DJ, Gerdil E, et al.
Two proof of concept clinical trials with TB vaccines demonstrate that new approaches can prevent sustained TB infection in adolescents (BCG revaccination) and TB disease in adults (M72/ASO1 E ) (Nemes et al., 2018; Tait et al., 2019) [1,2]. Both approaches are in late stage deve…
Khalid K, Poh CL
…c resistance crisis. To address this issue, next-generation vaccines are being developed to prevent antimicrobial resistance caused by MDR bacteria. Traditional vaccine platforms, such as inactivated vaccines (IVs) and live attenuated vaccines (LAVs), were effective in preventing…
Sirak A, Tulu B, Bayissa B, Gumi B, Berg S, et al.
Local immunological responses at the site of infections, such as at the lymph nodes and lungs, do play a role in containing infection caused by Mycobacterium bovis ( M. bovis ). This bovine tuberculosis (bTB) study was conducted to evaluate cellular and cytokine responses in the …
Carter A, Msemburi W, Sim SY, Gaythorpe KAM, Lambach P, et al.
Background The Immunization Agenda 2030 (IA2030) Impact Goal 1.1. aims to reduce the number of future deaths averted through immunization in the next decade. To estimate the potential impact of the aspirational coverage targets for IA2030, we developed an analytical framework and…
Jeyachandran DS, Pusam Y
…how these insights could catalyze the development of future vaccines. The current landscape of novel vaccine development for TB is illuminated, including a spotlight on the latest vaccine candidates.
Gregor Nosan, Andreja Cerkvenik Škafar
…s to modernize TB prevention while awaiting next-generation vaccines and may serve as a guide for other low-incidence countries.
Kanipe C, Putz EJ, Palmer MV
Bovine tuberculosis is mainly caused by Mycobacterium bovis. Bacillus Calmette-Guérin (BCG) is an attenuated strain of M. bovis which provides variable disease protection. Lesions have been characterized in infected cattle, but little comparison has been done with lesions which f…
Dijkman K, Lindenstrøm T, Rosenkrands I, Søe R, Woodworth JS, et al.
… resulting in ~1.6 million deaths annually. Protein subunit vaccines have shown promise against TB in clinical studies. Unfortunately, most subunit vaccines require multiple administrations, which increases the risk of loss to follow-up and necessitates more complex and costly lo…
Ręka G, Korzeniowska A, Piecewicz-Szczęsna H
The aim of the study Is to present the state of knowledge from April and May 2020 about the influence of Bacillus-Calmette-Guérin vaccination against tuberculosis on incidence and mortality due to COVID-19. Material and methods A review of the latest literature till 9 May 2020 ha…
Kwon KW, Choi HG, Kim KS, Park SA, Kim HJ, et al.
The quest for effective and enhanced multiantigenic tuberculosis (TB) subunit vaccine necessitates the induction of a protective pathogen-specific immune response while circumventing detrimental inflammation within the lung milieu. In line with this goal, we engineered a modified…
Wang H, Wang S, Fang R, Li X, Xing J, et al.
…fforts are underway to accelerate the development of new TB vaccines. However, challenges arise due to the limited immunogenicity and safety of these vaccines, necessitating adjuvants to bolster their ability to elicit a robust immune response for improved and safer immunization.…
Jessica E Rothman, Kenneth G Castro, Benjamin A Lopman, Neel R Gandhi, Kristin N Nelson
…to 2,486 (U.S.-born), within the range of established adult vaccines. **SUMMARY LINE:** Targeted vaccination of-infected high-risk persons with an M72/AS01-like vaccine could prevent one tuberculosis case per 217 (HIV) to 2,486 (U.S.-born) persons vaccinated, within the range of…
Wajja A, Namutebi M, Apule B, Oduru G, Kiwanuka S, et al.
…e for tuberculosis (TB) is a global public health priority. Vaccines under development will always need evaluation in endemic settings, most of which have limited resources. Adolescents are an important target population for a new TB vaccine and for other vaccines which are relev…
Angelidou A, Diray-Arce J, Conti MG, Smolen KK, van Haren SD, et al.
Vaccines have been traditionally developed with the presumption that they exert identical immunogenicity regardless of target population and that they provide protection solely against their target pathogen. However, it is increasingly appreciated that vaccines can have off-targe…
Wu Q, Zaid M, Xuan Z, Wang C, Gu H, et al.
…titis and tuberculosis, either by introducing adult booster vaccines or by research into more effective vaccines. Varicella and HFMD are on the rise, but vaccines for these are not included in national programs. Strategies funded by government agencies or encouraged by research i…
Blok BA, Arts RJW, van Crevel R, Aaby P, Joosten LAB, et al.
…inst tuberculosis, can potentiate immune responses to other vaccines through induction of trained innate immunity and heterologous adaptive immunity. We performed an explorative, randomized, noncontrolled open trial to investigate whether BCG vaccination increases humoral and cel…
Vierboom MPM, Chenine AL, Darrah PA, Vervenne RAW, Boot C, et al.
…ated different routes of administration of vectored subunit vaccines based on chimpanzee-derived adenovirus serotype-3 (ChAd3) for homologous prime-boosting and modified vaccinia virus Ankara (MVA) for heterologous boosting with both vaccine vectors expressing the same antigens f…
Pérez I, Uranga S, Sayes F, Frigui W, Samper S, et al.
…n a clinical isolate belonging to L4. Here we construct new vaccines based on isogenic gene deletions in clinical isolates of the L2 and L3 modern lineages. These three vaccine candidates were characterized at molecular level and also in animal experiments of protection and safet…
Bæk O, Schaltz-Buchholzer F, Campbell A, Amenyogbe N, Campbell J, et al.
…ntentionally targeted pathogen) effects of BCG and smallpox vaccines hold significant translational potential. Yet despite their use for centuries, how scar formation occurs and how local skin-based events relate to systemic effects that allow these two vaccines to deliver powerf…
Chatzikleanthous D, O'Hagan DT, Adamo R
…re are still unmet needs that may enable the development of vaccines suitable for more challenging pathogens (e.g., HIV and tuberculosis) and for cancer vaccines. Liposomes have already been shown to be highly effective as adjuvant/delivery systems due to their versatility and li…
van Meijgaarden KE, Li W, Moorlag SJCFM, Koeken VACM, Koenen HJPM, et al.
Bacillus Calmette-Guèrin - vaccination induces not only protection in infants and young children against severe forms of tuberculosis, but also against non-tuberculosis related all-cause mortality. To delineate different factors influencing mycobacterial growth control, here we f…
Joanna J Regan, Zanju Wang, Christina R Phares
… the 4 weeks following live-virus vaccination because these vaccines are thought to increase the risk of false-negative results. **METHODS:** We retrospectively analyzed TST and IGRA results for 158 484 US-bound immigrant and refugee children aged 2-14 years who received …